Results 21 to 30 of about 11,219 (248)
Assessment of the Myasthenia Gravis Patients’ Quality of Life
Pielęgniarstwo Neurologiczne i Neurochirurgiczne, 2023 Introduction. Myasthenia gravis is an immune-mediated disease associated with a disorder of the neuromuscular junction. MG belongs to the group of chronic diseases with variable clinical courses.
Weronika Jung-Plath +3 more
doaj +1 more source
Flow cytofluorimetric analysis of anti-LRP4 (LDL receptor-related protein 4) autoantibodies in Italian patients with Myasthenia gravis [PDF]
, 2015 Background: Myasthenia gravis (MG) is an autoimmune disease in which 90% of patients have autoanti-bodies against the muscle nicotinic acetylcholine receptor (AChR), while autoantibodies to muscle-specific tyrosine kinase (MuSK) have been detected in ...
Antonini, Giovanni +11 more
core +3 more sources
Eculizumab: A Review in Generalized Myasthenia Gravis [PDF]
Drugs, 2018 The humanized monoclonal antibody eculizumab (Soliris®) is a complement inhibitor indicated for use in anti-acetylcholine receptor (AChR) antibody-positive adults with generalized myasthenia gravis (gMG) in the USA, refractory gMG in the EU, or gMG with symptoms that are difficult to control with high-dose IVIg therapy or PLEX in Japan. It is the first
openaire +2 more sources
Clinical predictors for the prognosis of myasthenia gravis
BMC Neurology, 2017 Background Clinical predictors for myasthenia gravis relapse and ocular myasthenia gravis secondary generalization during the first two years after disease onset remain incompletely identified.
Lili Wang, Yun Zhang, Maolin He
doaj +1 more source
Eculizumab as a promising treatment in thymoma-associated myasthenia gravis
Therapeutic Advances in Neurological Disorders, 2020 Myasthenia gravis is a chronic autoimmune disorder caused by antibodies directed against the neuromuscular junction. Some patients may have an associated thymoma, which confers a worse prognosis.
Valentina Vélez-Santamaría +5 more
doaj +1 more source
Sotalol‐induced generalized and ocular myasthenia gravis [PDF]
Clinical Case Reports, 2019 Abstract We present a patient with end‐stage hypertrophic cardiomyopathy who was suffering from ocular and generalized forms of myasthenia gravis as an uncommon neurological complication of sotalol. This case report warns clinicians to maintain caution over rare side effects of medication, which could be confused with the clinical ...
Mohammadbagher Sharifkazemi, Farzad Ziya
openaire +3 more sources
Diplopia in a patient presenting with “blurred vision”: a case report
Journal of Medical Case Reports, 2023 Background Myasthenia gravis is an autoimmune condition affecting the neuromuscular junction and causing muscle weakness along with fatigue (myasthenia).
Anil Harrison +3 more
doaj +1 more source
Unraveling the role of ectopic thymic tissue in patients undergoing thymectomy for myasthenia gravis [PDF]
, 2019 Extended thymectomy has been considered the goal of surgery for myasthenia gravis (MG) mainly due to the existence of ectopic thymic tissue. Recently, ectopic thymic tissue has attracted increasing attention in patients with MG following thymectomy ...
Bauer, Gero +9 more
core +1 more source
Sensitivity of MG‐ADL for generalized weakness in myasthenia gravis [PDF]
European Journal of Neurology, 2018 Background and purposeMyasthenia gravis activities of daily living (MG‐ADL) is a commonly used questionnaire in MG trials. To investigate whether MG‐ADL is equally sensitive to oculobulbar and generalized weakness, its correlation with the oculobulbar and generalized domain of the quantitative myasthenia gravis (QMG) score was analyzed (QMGob and ...
Meel, R.H.P. de +4 more
openaire +3 more sources
risk factors and impact on quality of life [PDF]
, 2016 Objectives Emerging evidence suggests that fatigue in myasthenia gravis (MG) is a relevant problem that negatively impacts activities of daily living (ADL). The relationship between fatigue and quality of life (QoL) has never been systematically explored
Grittner, Ulrike +5 more
core +1 more source